https://www.selleckchem.com/products/eed226.html
The patients with sarcopenia (n=48, 39%) and those with myosteatosis (n=101, 82%) had significantly lower overall survival and cancer-specific survival rates than those without sarcopenia and those without myosteatosis, respectively. In multivariable analysis, in addition to the number of pathological risk factors, both sarcopenia (P0.01) and myosteatosis (P=0.04) were independent significant predictors of poor cancer-specific survival. In our experience, sarcopenia and myosteatosis are independent predictors of poor cancer-specific